Chinese CRO WuXi PharmaTech, alongside partner TruTag Technologies, is developing tiny, edible bar codes designed to prevent drug counterfeiting, and the technology cleared its first hurdle.
An Indian CRO that counts Johnson & Johnson, Novartis and Sanofi among its clients is under fire from the FDA for repeated quality control issues, the latest ding to the country's reputation as a go-to destination for outsourced drug development.
Two mid-size CROs are slated to merge and contend with the industry's titans, as Chiltern is buying Theorem Clinical Research in a move to strengthen its global presence.
Contract drugmaker Patheon inked a deal to manufacture Flexion Therapeutics' top prospect as it moves through clinical development.
Two years after Quintiles' trend-setting IPO, the CRO's private equity owners are still profiting from the company's continued growth, pocketing $545 million in a secondary offering.
Irish CRO Icon has signed on to be the exclusive service provider for a new U.K. biotech startup, planning to help the nascent company advance a trio of Novartis-developed drugs.
AMRI, rebuilding its business after a string of slow quarters, posted a profit for the first time in 12 months as it looks to hit its stride as a growing contract drug developer.
Parexel International, slashing jobs after a rough run, posted some modest revenue gains in its fiscal fourth quarter, and now the CRO is looking to build some momentum with a jump in new business.
CRO INC Research posted another quarter of double-digit revenue growth, lifting its 2015 guidance for the second time to account for a jump in new business.
Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO.
Covance, acquired by LabCorp for about $6 billion earlier this year, has picked former head of R&D Deborah Keller to take the reins as CEO Joseph Herring retires.
Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.
PRA Health Sciences is ticking up its full-year expectations after another quarter of revenue growth, counting on a steady stream of new business.
Icon is again reducing its revenue expectations for 2015 but increasing its profit guidance, counting on a big quarter of business wins to balance some sluggish backlog conversion.
Quintiles is going back to its earlier optimism for 2015, scaling up its previously reduced growth projections after posting a strong sales quarter.
Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its capacity to take a larger share of an expanding market.
Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.
PRA Health Sciences, looking to find the next generation of clinical researchers, is dialing up its recruitment pitch in hopes of meeting the escalating demand for CRO-run trials around the world.
The recently merged Huntingdon Life Sciences and Harlan Laboratories have convinced their investors to commit up to $125 million in equity financing, lining up the cash they'll need to move forward as a joint entity.
Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.